Emcitate (tiratricol) for MCT8 deficiency
The FDA is expected to decide on Emcitate for MCT8 deficiency by September 28, 2026, under a NDA from Egetis Therapeutics.
What is being decided
Egetis Therapeutics has a NDA under FDA review for Emcitate (tiratricol) in MCT8 deficiency. Priority review for a rare genetic disorder of thyroid hormone transport with no approved treatment.
What each outcome would mean
An approval starts a second race rather than ending the first one: specialty pharmacy setup, insurance review, and patient assistance typically take weeks even when everything goes right. Our guide to the 90 days after a rare disease approval explains the timeline and the moves families can make on day 1.
A complete response letter would mean the FDA declined to approve in the application's current form. CRLs are often about manufacturing or data presentation rather than efficacy, and resubmission is common. Either way, this page updates with the outcome and what it means.
Get notified when new trials open or existing trials change for your condition.
Our coverage
Frequently asked questions
When will the FDA decide on Emcitate?
The FDA's target decision date (PDUFA date) for Emcitate in MCT8 deficiency is September 28, 2026, disclosed by Egetis Therapeutics. The agency can act before this date and occasionally runs past it.
What is Emcitate being reviewed for?
Egetis Therapeutics submitted a NDA for Emcitate in MCT8 deficiency. Priority review for a rare genetic disorder of thyroid hormone transport with no approved treatment.
What happens after the Emcitate decision?
If approved, availability is not immediate: specialty pharmacy setup, insurance review, and patient assistance typically take weeks even when everything goes right. If the FDA issues a complete response letter, the application was not approved in its current form; CRLs are often about manufacturing or data presentation rather than efficacy, and sponsors frequently resubmit. This page updates with the outcome either way.
Where this date comes from
The FDA does not publish PDUFA dates; companies disclose them. This one comes from Egetis announcement. Dates can move, and the FDA can act early or late. This page rechecks against our calendar, which is re-verified weekly.